Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated poliovirus vaccine Sabin strain
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Inactivated poliovirus vaccine Sabin strain (sIPV) is a **killed-virus (inactivated) vaccine** prepared from attenuated Sabin strains of poliovirus types 1, 2, and 3. Unlike oral poliovirus vaccine (OPV), which uses live attenuated virus, sIPV is administered by injection and cannot revert to a virulent form or cause vaccine-derived poliovirus. sIPV induces systemic immunity and partial mucosal immunity by stimulating neutralizing antibodies to poliovirus types 1, 2, and 3, preventing paralytic poliomyelitis. It is used for primary immunization and outbreak response, including against circulating vaccine-derived poliovirus type 2 (VDPV2). sIPV is used in several countries (notably in China and Japan), is considered immunogenic, and is being developed as a safer alternative to Salk strain IPV due to biosecurity concerns with the production of wild-type strains[1][2][3].
- Brand names
- Eupolio
- Other names
- sabin inactivated poliovirus vaccinesabin-IPVsIPV
Beyond the preview
Go deeper on inactivated poliovirus vaccine Sabin strain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated poliovirus vaccine Sabin strain.